ArticleCancer chemotherapy and pharmacology2025
An exposure-safety analysis to support the dosage of the novel AKT inhibitor capivasertib.
Carlos Fernandez Teruel et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it